Previously demonstrated survival benefits of crizotinib (Xalkori, Pfizer Inc.) as an adjuvant treatment for advanced ALK-positive non-small cell lung cancer (ALK+NSCLC) did not extend to the setting ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

Adults in England and Wales with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) will soon have access to a new first-line treatment. The National Institute for ...

Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of ...

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with ...

Effectiveness and safety of the amivantamab to lazertinib versus lazertinib alone in EGFR mutant metastatic non-small-cell lung cancer: Systematic review and meta-analysis. Exploring the prognostic ...

Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of ...

Multiple ALK inhibitors are now FDA approved for management of ALK-positive non-small cell lung cancer. A new study provides the second interim analysis of the phase III ATLA-1L trial of 275 treatment ...

In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the ...

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors ...